[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2469941A1 - Nouveaux acides nucleiques et polypeptides - Google Patents

Nouveaux acides nucleiques et polypeptides Download PDF

Info

Publication number
CA2469941A1
CA2469941A1 CA002469941A CA2469941A CA2469941A1 CA 2469941 A1 CA2469941 A1 CA 2469941A1 CA 002469941 A CA002469941 A CA 002469941A CA 2469941 A CA2469941 A CA 2469941A CA 2469941 A1 CA2469941 A1 CA 2469941A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
protein
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002469941A
Other languages
English (en)
Inventor
Y. Tom Tang
Vinod Asundi
Ryle W. Goodrich
Feiyan Ren
Jie Zhang
Qing A. Zhao
Jian-Rui Wang
Malabika J. Ghosh
Aidong J. Xue
Tom Wehrman
Gezhi Weng
Ping Zhou
Radoje T. Drmanac
Zhiwei Wang
Yunqing Ma
Dunrui Wang
Rui-Hong Chen
Chongjun Xu
Bryan J. Boyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/128,558 external-priority patent/US20040219521A1/en
Application filed by Individual filed Critical Individual
Publication of CA2469941A1 publication Critical patent/CA2469941A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux acides nucléiques, de nouvelles séquences polypeptidiques codées par lesdits acides nucléiques et leurs utilisations.
CA002469941A 2001-12-10 2002-12-10 Nouveaux acides nucleiques et polypeptides Abandoned CA2469941A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US33973901P 2001-12-10 2001-12-10
US60/339,739 2001-12-10
US33945301P 2001-12-11 2001-12-11
US60/339,453 2001-12-11
US36538402P 2002-03-14 2002-03-14
US36509102P 2002-03-14 2002-03-14
US60/365,384 2002-03-14
US60/365,091 2002-03-14
US37238102P 2002-04-12 2002-04-12
US37261502P 2002-04-12 2002-04-12
US60/372,381 2002-04-12
US60/372,615 2002-04-15
US10/128,558 2002-04-22
US10/128,558 US20040219521A1 (en) 2000-01-21 2002-04-22 Novel nucleic acids and polypeptides
US37604502P 2002-04-24 2002-04-24
US60/376,045 2002-04-24
PCT/US2002/039555 WO2003054152A2 (fr) 2001-12-10 2002-12-10 Nouveaux acides nucleiques et polypeptides

Publications (1)

Publication Number Publication Date
CA2469941A1 true CA2469941A1 (fr) 2003-07-03

Family

ID=27574889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002469941A Abandoned CA2469941A1 (fr) 2001-12-10 2002-12-10 Nouveaux acides nucleiques et polypeptides

Country Status (4)

Country Link
EP (1) EP1504099A4 (fr)
AU (1) AU2002366951A1 (fr)
CA (1) CA2469941A1 (fr)
WO (1) WO2003054152A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9315698U1 (de) * 1993-10-14 1993-12-23 BÜCHI LABORATORIUMS-TECHNIK AG, Flawil Verdampfer-Kolben für einen Rotationsverdampfer
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
CA2633171C (fr) 2001-06-20 2012-11-20 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
US20030068691A1 (en) * 2001-07-16 2003-04-10 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
CA2458818A1 (fr) * 2001-08-30 2003-04-10 Nuvelo, Inc. Procedes et materiaux relatifs aux polynucleotides et polypeptides de type facteur de croissance de cellules souches
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
EP1562969A4 (fr) 2002-03-28 2006-07-05 Bristol Myers Squibb Co Nouvelle proteine de surface cellulaire avec replis d'hemoglobine, bgs-19
ES2307933T3 (es) * 2002-04-26 2008-12-01 Astellas Pharma Inc. Proteina de 35 kda.
WO2004005335A2 (fr) * 2002-07-05 2004-01-15 Borean Pharma A/S Hormone de croissance multimerisee
ATE493433T1 (de) 2002-09-11 2011-01-15 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
WO2004031411A2 (fr) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes et polypeptides associes aux cancers du pancreas chez l'homme
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
WO2005030955A1 (fr) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Proteine exprimee dans une cellule nk
ATE423200T1 (de) * 2003-10-30 2009-03-15 Kazusa Dna Res Inst Foundation Neues plexin-polypeptid, dieses codierende dna und verwendung davon
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005072419A2 (fr) * 2004-01-27 2005-08-11 Nuvelo, Inc. Facteur proliferatif gastro-intestinal et utilisations de celui-ci
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7901881B2 (en) 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
CA2567520A1 (fr) 2004-06-01 2005-12-15 Genentech, Inc. Conjugues anticorps-maytansinoides
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
WO2006008294A2 (fr) * 2004-07-23 2006-01-26 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3088004B1 (fr) 2004-09-23 2018-03-28 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
CA2607291A1 (fr) 2005-05-12 2006-11-23 Steven D. Levin Compositions et procedes permettant de moduler des reponses immunitaires
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof
DK1937815T3 (en) 2005-09-13 2015-08-03 Nat Res Council Canada Methods and compositions for the modulation of tumor cell activity
GB0522113D0 (en) * 2005-10-28 2005-12-07 Ares Trading Sa vWFA-domain containing proteins
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
GB0615287D0 (en) * 2006-08-01 2006-09-06 Ares Trading Sa Integral membrane protein
JP2010505868A (ja) * 2006-10-02 2010-02-25 ザ スクリプス リサーチ インスティチュート エーテル脂質シグナル伝達経路を制御する酵素
GB0620735D0 (en) * 2006-10-18 2006-11-29 Ares Trading Sa Proteins
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
WO2009026660A1 (fr) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Marqueur de cellules dendritiques et son utilisation
ES2908934T3 (es) 2007-10-04 2022-05-04 Zymogenetics Inc ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
EP2217697B1 (fr) * 2007-11-08 2015-06-10 Biogen MA Inc. Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
AU2009233708B2 (en) 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2011519959A (ja) * 2008-05-13 2011-07-14 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 破壊された細胞膜を有する細胞、病原体に感染した細胞、死にかけている細胞または死細胞を検出する方法
EP2315779A2 (fr) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
MX2011008044A (es) 2009-02-03 2012-01-12 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre.
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (fr) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir
AU2010268690B2 (en) 2009-07-03 2011-11-10 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011004404A1 (fr) * 2009-07-10 2011-01-13 Decode Genetics Ehf Variantes génétiques pour prédire le risque de glaucome
EP2475391B1 (fr) 2009-09-09 2018-09-12 Centrose, LLC Conjugués médicamenteux ciblés à visée extracellulaire
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011075786A1 (fr) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
CN103068406B (zh) 2010-06-08 2017-06-30 基因泰克公司 半胱氨酸改造的抗体和偶联物
PE20171640A1 (es) 2010-09-22 2017-11-09 Alios Biopharma Inc Analogos de nucleotidos sustituidos
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
EP3103810A3 (fr) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CA2841745A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux proteines rspo et leurs utilisations
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
NZ626742A (en) 2012-02-22 2016-06-24 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
EA032038B1 (ru) 2012-07-13 2019-03-29 Онкомед Фармасьютикалс, Инк. Rspo3-связывающие агенты и их применение
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
WO2014096365A1 (fr) 2012-12-21 2014-06-26 Spirogen Sàrl Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
EP2935268B2 (fr) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazépines et conjugués associés
CA2904044C (fr) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines et leurs conjugues
EP2968596B1 (fr) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
CA2918139A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Lingo‐1拮抗薬及び脱髄障害の治療のための使用
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3353210B1 (fr) 2015-09-25 2024-11-06 Genentech, Inc. Anticorps anti-tigit et méthodes d'utilisation
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック, インコーポレイテッド 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
MX2020003089A (es) 2017-09-20 2020-10-15 Ph Pharma Co Ltd Analogos de tailanstatina.
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3841123A2 (fr) 2018-08-23 2021-06-30 Seagen Inc. Anticorps anti-tigit
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (fr) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Inducteurs chimiques conjugues de degradation et methodes d'utilisation
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées

Also Published As

Publication number Publication date
AU2002366951A1 (en) 2003-07-09
EP1504099A2 (fr) 2005-02-09
WO2003054152A2 (fr) 2003-07-03
WO2003054152A3 (fr) 2004-12-16
EP1504099A4 (fr) 2006-05-10

Similar Documents

Publication Publication Date Title
US6610536B2 (en) Nucleic acids and polypeptides
US6743619B1 (en) Nucleic acids and polypeptides
CA2469941A1 (fr) Nouveaux acides nucleiques et polypeptides
US20040048249A1 (en) Novel nucleic acids and secreted polypeptides
CA2440257A1 (fr) Nouveaux acides nucleiques et polypeptides
CA2402563A1 (fr) Nouveaux acides nucleiques et polypeptides
CA2399776A1 (fr) Acides nucleiques et polypeptides
CA2460621A1 (fr) Nouveaux acides nucleiques et polypeptides
EP1325120A2 (fr) Acides nucleiques et polypeptides
CA2461280A1 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A2 (fr) Nouveaux acides nucleiques et polypeptides
US20040053245A1 (en) Novel nucleic acids and polypeptides
US20020146692A1 (en) Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
CA2440747A1 (fr) Nouveaux acides nucleiques et nouveaux polypeptides
CA2401505A1 (fr) Nouveaux acides nucleiques et polypeptides
WO2004087874A2 (fr) Acides nucleiques et polypeptides
CA2456955A1 (fr) Nouveaux acides nucleiques et polypeptides secretes
US20070060743A1 (en) Novel nucleic acids and polypeptides
US20040044181A1 (en) Novel nucleic acids and polypeptides
US20050221342A1 (en) Nucleic acids and polypeptides
WO2003025142A2 (fr) Nouveaux acides nucleiques et polypeptides secretes
CA2409164A1 (fr) Nouveaux acides nucleiques et polypeptides
US20030235883A1 (en) Novel nucleic acids and polypeptides
EP1268762A1 (fr) Nouveaux acides nucleiques et polypeptides
US20050175607A1 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
FZDE Discontinued